Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
- Associated Therapies
- -
Naproxen on Tooth Sensitivity Caused by In-office Bleaching
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Universidade Federal de Sergipe
- Target Recruit Count
- 50
- Registration Number
- NCT02463552
- Locations
- 🇧🇷
Universidade Federal de Sergipe, Aracaju, SE, Brazil
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
- Conditions
- Interventions
- Other: Lab WorkDrug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)Drug: Certolizumab pegol (CDP870, tradename Cimzia)Drug: HydroxychloroquineDrug: SulfasalazineDrug: MedrolDrug: PrednisoneDrug: TriamcinoloneDrug: NaproxenDrug: LeflunomideDrug: MethotrexateDrug: humira
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT02451748
- Locations
- 🇺🇸
Outpatient Care Center, Chicago, Illinois, United States
Pilot Study of OXP005 to Assess Gastroduodenal Irritation
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Oxford Pharmascience Ltd
- Registration Number
- NCT02408978
- Locations
- 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom
Naproxen for Pain Control With Intrauterine Device Insertion
- Conditions
- Interventions
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Planned Parenthood League of Massachusetts
- Target Recruit Count
- 119
- Registration Number
- NCT02388191
- Locations
- 🇺🇸
Planned Parenthood League of Massachusetts, Boston, Massachusetts, United States
NSAIDs for Pain After Ankle Fracture Surgery
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Northwell Health
- Registration Number
- NCT02281968
PF-06372865 In Subjects With Chronic Low Back Pain
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 302
- Registration Number
- NCT02262754
- Locations
- 🇺🇸
S&W Clinical Research, Fort Lauderdale, Florida, United States
🇺🇸Neuro-Pain Medical Center, Fresno, California, United States
🇺🇸Pines Clinical Research Inc., Pembroke Pines, Florida, United States
Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02202512
- Locations
- 🇩🇪
1333.43.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 390
- Registration Number
- NCT02183038
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1790
- Registration Number
- NCT02139046
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 189
- Registration Number
- NCT02128490
- Locations
- 🇺🇸
Benny Green MD PA Family Practice, Little Rock, Arkansas, United States
🇺🇸Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸Central Kentucy Reseach Associates, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.